**4.3. Results**

Results of lipid parameters presented in Table 7 confirm the highly significant increased concentration of analyzed lipid and lipoprotein parameters in LEAD-patients (p<0.0001), compared to control values. The low values of the SAAR, which is generally low (< 10.8) in the atherogenic lipoprotein phenotype, also confirms the atherogenic lipoprotein constellation in the serum of LEAD-patients.


**Table 7.** Serum concentration of lipids, lipoproteins, and SAAR-score in LEAD-patients vs. control group


**Table 8.** Serum concentration of lipids, lipoproteins, and SAAR-score in lower extremity arterial disease

In 80% of patients (Table 8), LEAD was associated with an atherogenic lipoprotein phenotype. An increased concentration of small dense LDL (LDL3-7 subgroups) in the LEAD-patients with an atherogenic lipoprotein profile, compared to the results from the LEAD-patients with a nonatherogenic lipoprotein profile (p<0.0001), confirms the predominance of atherogenic lipo‐ proteins in serum in the subgroup of patients with an atherogenic lipoprotein profile.
